Advertisement
Advertisement
LRMR
Larimar Therapeutics, Inc. Common Stock
4.84
USDSponsored
+0.16
+3.50%
Mar 26, 15:59 UTC -4
Closed
After-Market
4.83
-0.02
-0.39%
LRMR Earnings Reports
Positive Surprise Ratio
LRMR beat 25 of 38 last estimates.
66%
Next Report
Date of Next Report
Apr 28, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.52
Implied change from Q4 25 (Revenue/ EPS)
--
/-28.77%
Implied change from Q1 25 (Revenue/ EPS)
--
/+13.04%
Larimar Therapeutics, Inc. Common Stock earnings per share and revenue
On Mar 19, 2026, LRMR reported earnings of -0.73 USD per share (EPS) for Q4 25, missing the estimate of -0.51 USD, resulting in a -41.17% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +3.95% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 10 analysts forecast an EPS of -0.52 USD, with revenue projected to reach -- USD, implying an decrease of -28.77% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Context Therapeutics Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.14
Surprise
-29.39%
Avalo Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.49
Actual
-$1.12
Surprise
+24.33%
Journey Medical Corporation Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.04
Surprise
+31.86%
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-Surprise
-
Achieve Life Sciences, Inc.
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.12%
Vivani Medical, Inc. Common Stock (DE)
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.09
Surprise
-
Pyxis Oncology, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Acrivon Therapeutics, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.47
Actual
-$0.52
Surprise
-9.34%
Fractyl Health, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
$0.15
Surprise
+181.70%
NRX Pharmaceuticals, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
$0.00
Actual
-$0.01
Surprise
-361.54%
FAQ
What were Larimar Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Larimar Therapeutics, Inc. Common Stock reported EPS of -$0.73, missing estimates by -41.17%, and revenue of $0.00, 0% as expectations.
How did the market react to Larimar Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 3.95%, changed from $4.30 before the earnings release to $4.47 the day after.
When is Larimar Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Apr 28, 2026.
What are the forecasts for Larimar Therapeutics, Inc. Common Stock's next earnings report?
Based on 10
analysts, Larimar Therapeutics, Inc. Common Stock is expected to report EPS of -$0.52 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement